Latest Oncology News

ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

December 17th 2025

Samantha A. Armstrong, MD

Drs Armstrong and Tawagi highlight chronic lymphocytic leukemia updates from the 2025 ASH Annual Meeting.

Ciforadenant Plus Ipilimumab/Nivolumab Is Safe But Does Not Boost Efficacy in Frontline ccRCC

December 16th 2025

Kyle Doherty

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

Denosumab Displays Tolerability, Combination Potential in AYA Osteosarcoma

December 16th 2025

Kyle Doherty

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

FDA Expands the Indications of 2 Tests to Identify Patients With HER2+ Breast Cancer Eligible for T-DXd

December 16th 2025

Kyle Doherty

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

FDA Grants Fast Track Designation to Muzastotug Plus Pembrolizumab in MSS mCRC

December 16th 2025

Caroline Seymour

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Latest Oncology Videos

Dr Forsberg on the Impact of the MajesTEC-3 Trial in Relapsed/Refractory Myeloma

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Stein on the FDA Approval of Revumenib for R/R, NPM1-Mutant AML

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Biomarkers, Disease Tracking, and Tumor Evolution

Balancing Intensity, Duration, and Maintenance in Treatment

Integrating Immunotherapy – Lessons from Small Cell Lung Cancer

Recognizing and Treating AVPC

Individualizing Chemotherapy: Dosing, Tolerability, and Treatment Duration

Treatment Options for High Grade (Grade 3) NETS

Exploring Potential Implications of CHOPIN Trial Data in Metastatic Uveal Melanoma

Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

Sequencing of Systemic NETS Treatments

CHOPIN Trial: Percutaneous Hepatic Perfusion Plus Nivolumab/Ipilimumab in Metastatic Uveal Melanoma

Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

Dr Shah on Current Guidelines for Diagnosing Cancer-Associated LEMS

Dr Patel on MRD Responses With Inotuzumab Ozogamicin Plus Dasatinib in Ph+ ALL

NSCLC Case Study 2: A Never-Smoker with Neuroendocrine Markers

Deciphering Biomarker Results for Adjuvant Immunotherapy in NSCLC

Improving Workflow and ctDNA Adoption in MIBC Care

The Role of DNA & RNA in Comprehensive Genomic Profiling

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

All Oncology News

Joint Study Finds Proton Beam Therapy Helps Patients With Throat Cancer Live Longer With Fewer Side Effects

December 16th 2025

Mayo Clinic

Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC

December 16th 2025

Riley Kandel

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

First AACR Pediatric Cancer Progress Report Highlights Prominent Progress, Impending Issues in the Field

December 16th 2025

Riley Kandel

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

ASCENT-03 Data Show Consistent Safety With Sacituzumab Govitecan in Previously Untreated Advanced TNBC

December 16th 2025

Kristi Rosa

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma

December 15th 2025

Riley Kandel

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

Sentinel Lymph Node Biopsy Omission Shows Feasibility in Select HR+ Breast Cancer

December 15th 2025

Gina Mauro

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer

December 15th 2025

Chris Ryan

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in R/R Myeloma

December 15th 2025

Chris Ryan

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

UCSF Study Finds a Better Way to Screen for Breast Cancer

December 15th 2025

UCSF Health

Researchers at UCSF share results about individualized breast cancer screenings from the WISDOM study.

Varegacestat Hits Phase 3 PFS End Point in Progressing Desmoid Tumors

December 15th 2025

Chris Ryan

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Kristi Rosa

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

PD-L1 Testing in NSCLC: A Practical Guide for Oncologists

December 15th 2025

David Carbone, MD, PhD

Experts discuss the practical use and limitations of PD-L1 testing in NSCLC. They confirm that testing is standard for all patients, but note results can vary between different PD-L1 test platforms, requiring quality-controlled assays.

Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes

December 15th 2025

Kyle Doherty

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Five Under 5: Top Oncology Videos for the Week of 12/7

December 14th 2025

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

Russ Conroy

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

See All News